Inhibitory Immune Checkpoint panel 1 - Human WB (ab278172)
Overview
-
Product name
Inhibitory Immune Checkpoint panel 1 - Human WB -
Species reactivity
Reacts with: Human -
Product overview
Inhibitory immune checkpoint panel 1 - Human WB ab278172 contains multiple trial-sized versions of anti-human antibody clones against PD-L1, PD-L2, PD1, LAG3, TIM 3, VISTA, CTLA4 and TIGIT specifically selected for high performance in various applications. They are provided as a sampler panel to allow you to easily evaluate each antibody.
For guidelines on how to use each antibody within the panel, please consult the individual datasheet for each antibody.
Panel contains:
- Rabbit monoclonal [73-10] to PD-L1 (20 μL) ab228415
- Rabbit monoclonal [EPR1163(2)] to PD-L2 (20 μL) ab187662
- Rabbit monoclonal [EPR23119-111] to PD1 (20 μL) ab243644
- Rabbit monoclonal [EPR20261] to LAG-3 (20 μL) ab209236
- Rabbit monoclonal [EPR22241] to TIM 3 (20 μL) ab241332
- Rabbit monoclonal [EPR21050] to VISTA (20 μL) ab230950
- Rabbit monoclonal [CAL49] to CTLA4 (20 μL) ab237712
- Rabbit monoclonal [BLR047F] to TIGIT - BSA free (20 μL) ab243903
-
Notes
Explore our range of antibody sample panels designed to provide you with a variety of trial-size antibodies in a convenient and cost-effective format.
Directly conjugated versions of our antibodies are available and ready to use for multicolor flow cytometry or immunocytochemistry analysis. Please refer to the ‘Associated products’ section below.
Carrier-free formulations of our recombinant antibodies are also available for easy conjugation to labels of your choice and for multiplex applications. Please refer to the ‘Associated products’ section below.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 1 kit ab237712 - Anti-CTLA4 antibody [CAL49] 2 x 10µl ab209236 - Anti-Lymphocyte Activation Gene 3 antibody [EPR20261] 2 x 10µl ab243644 - Anti-PD1 antibody [EPR23119-111] 2 x 10µl ab228415 - Anti-PD-L1 antibody [73-10] 2 x 10µl ab187662 - Anti-PD-L2 antibody [EPR1163(2)] 2 x 10µl ab243903 - Anti-TIGIT antibody [BLR047F] 2 x 10µl ab241332 - Anti-TIM 3 antibody [EPR22241] 2 x 10µl ab230950 - Anti-VISTA antibody [EPR21050] 2 x 10µl -
Research areas
-
Cellular localization
CTLA4: Cell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and. TIM 3: Membrane. Cell junction. Localizes to the immunological synapse between CD8+ T-cells and target cells. PD-L2: Secreted; Cell membrane and Endomembrane system. PD1: Membrane. LAG-3: Membrane. PD-L1: Cell membrane and Endomembrane system. VISTA: Membrane. TIGIT: Cell membrane. -
Database links
- Entrez Gene: 1493 Human
- Entrez Gene: 201633 Human
- Entrez Gene: 29126 Human
- Entrez Gene: 3902 Human
- Entrez Gene: 5133 Human
- Entrez Gene: 64115 Human
- Entrez Gene: 80380 Human
- Entrez Gene: 84868 Human
see all
Images
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB
All lanes: Anti-PD-L1 antibody [73-10] (ab228415) at 1/1000 dilution.
Lane 1: NCI-H1975 (human non-small cell lung cancer cell line), whole cell lysate, 20 ug.
Lane 2: Human placenta, 20 ug.
Lane 3: Human thymus, 20 ug.
Secondary (all lanes): ab97051 at 1/50000 dilution.
Predicted MW: 33 kDa.
Observed MW: The molecular mass observed is consistent with what has been described in the literature (PMID: 26546452).
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 70 seconds.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WBAll lanes: Anti-PD-L1 antibody [73-10] (ab228415) at 1/1000 dilution.
Lane 1: MDA-MB-231 (Human breast adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 2: MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 3: SK-BR-3 (Human breast adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 4: H1975 (Human non-small cell lung cancer epithelial cell) whole cell lysate, 20 ug.
Lane 5: NCI-H1299 (Human lung carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 6: A549 (Human lung carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 7: SW480 (Human colorectal adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 8: HCT 116 (Human colorectal carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 9: PC-3 (Human prostate adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 10: DU 145 (Human prostate carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 11: A375 (Human malignant melanoma epithelial cell) whole cell lysate, 20 ug.
Lane 12: MeWo (Human malignant melanoma fibroblast) whole cell lysate, 20 ug.
Lane 13: U-87 MG (Human glioblastoma-astrocytoma epithelial cell) whole cell lysate, 20 ug.
Lane 14: Huh7 (Human hepatocellular carcinoma epithelial cell) whole cell lysate, 20 ug.Lane 15: HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 16: BXPC-3 (Human pancreas adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 17: PANC-1 (Human pancreatic epithelioid carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 18: NIH:OVCAR-3 (Human ovary adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 19: SK-OV-3 (Human ovarian cancer epithelial cell) whole cell lysate, 20 ug.
Lane 20: HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate, 20 ug.Secondary (all lanes): ab97051 at 1/20000 dilution.
Predicted MW: 33 kDa.
Observed MW: 40-60kDa.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 120 seconds.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB -
Western blot - Inhibitory immune checkpoint panel 1 - human WB (ab278172)All lanes: Anti-PD1 antibody [EPR23119-111] (ab243644) at 1/1000 dilution.
Lane 1: Untreated MOLT-4 (human lymphoblastic leukemia T lymphoblast), 20 ug.
Lane 2: MOLT-4 treated with 500ng/ml Ionomycin and 10ng/ml Phorbol-12-myristate-13-acetate (PMA) for 24 hours, 20 ug.
Secondary (all lanes): ab131366 at 1/1000 dilution
Predicted MW: 32 kDa.
Observed MW: 50-55kDa. The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 30487606, 31783892).
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 48 seconds. This blot was developed using a higher sensitivity ECL substrate.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB (ab278172)All lanes: Anti-PD1 antibody [EPR23119-111] (ab243644) at 1/1000 dilution.
Lane 1: Human tonsil tissue lysate, 20 ug.
Lane 2: Human tonsil tissue lysate treated with PNGase F, 20 ug.
Secondary (all lanes): ab131366 at 1/1000 dilution
Predicted MW: 32 kDa.
Observed MW: 50-55kDa. The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 30487606, 31783892).
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 48 seconds. This blot was developed using a higher sensitivity ECL substrate.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB (ab278172)All lanes: Anti-LAG-3 antibody [EPR20261] (ab209236) at 1/1000 dilution.
Lane 1: Human LAG3 Fc chimera recombinant protein (aa23-450), 0.01 ug.
Secondary (all lanes): ab97051 at 1/100000 dilution.
Predicted MW: 57 kDa.
Observed MW: 90 kDa.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 1 second.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB (ab278172)All lanes: Anti-TIM 3 antibody [EPR22241] (ab241332) at 1/1000 dilution.
Lane 1: Daudi (human Burkitt's lymphoma cell line) whole cell lysate, 20 ug.
Lane 2: Daudi whole cell lysate (treated with PNGase F), 20 mg/ml.
Lane 3: RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate, 20 ug.
Lane 4: RAW 264.7 whole cell lysate (treated with PNGase F), 20 ug.
Secondary (all lanes): ab97051 at 1/20000 dilution.
Predicted MW: 33 kDa.
Observed MW: 40 kDa, 50-60kDa (glycosylated form)
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 70 seconds. Lanes 3 & 4 were developed using a higher sensitivity ECL substrate.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB (ab278172)All lanes: Anti-VISTA antibody [EPR21050] (ab230950) at 1/1000 dilution.
Lane 1: Human fetal spleen lysate, 20 ug.
Lane 2: Human thymus lysate, 20 ug.
Lane 3: DU145 (Human prostate carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 4: Human fetal lung lysate, 20 ug.
Secondary (all lanes): ab97051 at 1/20000 dilution.
Predicted MW: 34 kDa.
Observed MW: The 50-60 kda band observed is the glycosylated form of VISTA, consistent with what has been described in the literature (PMID: 29216931).
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: Lanes 1-2: 32 seconds; Lanes 3-4: 6 seconds.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB (ab278172)All lanes: Anti-CTLA4 antibody [CAL49] (ab237712) at 1/1000 dilution.
Lane 1: Untreated human PBMC (human peripheral blood mononuclear cell) whole cell lysate, 20 ug.
Lane 2: Human PBMC (treated with 10μg/ml PHA for 2 days) whole cell lysate, 20 ug.
Lane 3: Untreated mouse splenocyte whole cell lysate, 20 ug.
Lane 4: Mouse splenocyte (treated with 2.5μg/ml Concanavalin A (ConA) for 3 days) whole cell lysate, 20 ug.
Secondary (all lanes): ab97051 at 1/100000 dilution.
Predicted MW: 25 kDa.
Observed MW: 25 kDa.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
-
Western blot - Inhibitory immune checkpoint panel 1 - human WB (ab278172)All lanes: Anti-TIGIT antibody [BLR047F] - BSA free (ab243903) at 1/1000 dilution.
Lane 1: HeLa cell whole cell lysate, 50 ug.
Lane 2: HEK-293T cell whole cell lysate, 50 ug.
Lane 3: MyLa CD4+ whole cell lysate, 50 ug.
Lane 4: HepG2 whole cell lysate, 50 ug.
Lane 5: MG whole cell lysate, 50 µg.
Lane 6: Jurkat whole cell lysate, 50 µg.
Lane 7: GaMG whole cell lysate, 50 µg.
Lane 8: A549 whole cell lysate, 50 µg.
Secondary (all lanes): HRP-conjugated goat anti-rabbit IgG antibody.
Predicted MW: 26 kDa.
Exposure time: 3 minutes.
Detection: chemiluminescence